Adverse Effects versus Convenience of the COVID-19 Viral-Vector Vaccines | PTCE Connect

Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education. Adverse Effects versus Convenience of the COVID-19 Viral-Vector Vaccines Educational Objectives: Articulate the benefits of viral-vector vaccines compared with the risk of thrombosis with thrombocytopenia syndrome (TTS) Elaborate on current viral-vector TTS adverse effect incidence data and risk among patients who have received or will receive a viral-vector vaccine Faculty: James Lewis, PharmD, FIDSA ID Clinical Pharmacy Supervisor Oregon Health & Sciences University Portland, Oregon James Lewis, PharmD, FIDSA, has no financial relationships with commercial interests to disclose. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-21-264-H06-P. The activity is available for CE credit through June 29, 2022. This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP. See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices